We also observe Kv3.4 expression on the synapses of humanneurons making it a promising target for the development of noveltherapeutic agents that seek to modulate Kv3.4 expression and/or functionfor the treatment of Alzheimer’s disease, and potentially other centralnervous system (CNS) diseases. This evidence concerns the gene KCNC4 and Alzheimer disease.